Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: Involvement of intracellular signaling pathways

Neuroscience

Volumn 238, Issue , 2013, Pages 185-194

  Cunha, M P ^a,b,d   Martin de Saavedra M D ^a,b   Romero, A ^a,b,e   Parada, E ^a,b   Egea, J ^a,b,c   del Barrio, L ^a,b   Rodrigues, A L S ^d   Lopez M G ^a,b,c  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

6 OHDA; AKT; Creatine; GSK 3 ; Neuroprotection; PKA

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CHELERYTHRINE; CREATINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C;

ARTICLE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION;

CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CREATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROBLASTOMA; NEURONS; OXIDOPAMINE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84875600348     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.02.030     Document Type: Article

References (91)

1. + toxicity in an organotypic tissue culture system. Cell Transplant 2005, 14:537-550.
2. Andres R.H., Huber A.W., Schlattner U., Pérez-Bouza A., Krebs S.H., Seiler R.W., Wallimann T., Widmer H.R. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience 2005, 133:701-713.
3. Bakos J., Strbak V., Ratulovska N., Bacova Z. Effect of oxytocin on neuroblastoma cell viability and growth. Cell Mol Neurobiol 2012, 32:891-896.
4. Beal M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2009, 3:S189-S194.
5. Behrens M.M., Strasser U., Koh J.Y., Gwag B.J., Choi D.W. Prevention of neuronal apoptosis by phorbol ester-induced activation of protein kinase C: blockade of p38 mitogen-activated protein kinase. Neuroscience 1999, 94:917-927.
6. Bender A., Koch W., Elstner M., Schombacher Y., Bender J., Moeschl M., Gekeler F., Müller-Myhsok B., Gasser T., Tatsch K., Klopstock T. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006, 67:1262-1264.
7. Bessman S.P., Geiger P.J. Transport of energy in muscle: the phosphoryl creatine shuttle. Science 1981, 211:448-452.
8. Blandini F., Armentero M.T., Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008, 14:S124-S129.
9. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006, 59:1144-1150.
10. Bloom M.Z. NIH announces phase III clinical trial of creatine for Parkinson's disease. Consult Pharm 2007, 22:378.
11. Braissant O., Henry H., Loup M., Eilers B., Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Brain Res Mol Brain Res 2001, 86:193-201.
12. Brewer G.J., Wallimann T.W. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem 2000, 74:1968-1978.
13. Brustovetsky N., Brustovetsky T., Dubinsky J.M. On the mechanisms of neuroprotection by creatine and phosphocreatine. J Neurochem 2001, 76:425-434.
14. Cadet J.L., Katz M., Jackson-Lewis V., Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 1989, 476:10-15.
15. Carrasco E., Werner P., Casper D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci Lett 2008, 441:44-49.
16. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18:1162-1164.
17. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990, 265:5267-5272.
18. Dal-Cim T., Molz S., Egea J., Parada E., Romero A., Budni J., Martín de Saavedra M.D., del Barrio L., Tasca C.I., López M.G. Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3β pathway. Neurochem Int 2012, 61:397-404.
19. Davie C.A. A review of Parkinson's disease. Br Med Bull 2008, 86:109-127.
20. Deldicque L., Theisen D., Bertrand L., Hespel P., Hue L., Francaux M. Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and Akt/PKB pathways. Am J Physiol Cell Physiol 2007, 293:C1263-C1271.
21. Deng C., Tao R., Yu S.Z., Jin H. Sulforaphane protects against 6-hydroxydopamine-induced cytotoxicity by increasing expression of heme oxygenase-1 in a PI3K/Akt-dependent manner. Mol Med Report 2012, 5:847-851.
22. Doré S., Takahashi M., Ferris C.D., Hester L.D., Guastella D., Snyder S.H. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci U S A 1999, 96:2445-2450.
23. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
24. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
25. Dwivedi Y., Janicak P.G., Pandey G.N. Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients. Psychopharmacology 1998, 138:47-54.
26. Frame S., Cohen P. GSK3 takes centre stage more than 20years after its discovery. Biochem J 2001, 359:1-16.
27. Gasser T. Mendelian forms of Parkinson's disease. Biochim Biophys Acta 2009, 1792:587-596.
28. Ge K.L., Chen W.F., Xie J.X., Wong M.S. Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways. J Ethnopharmacol 2010, 127:118-123.
29. Genius J., Geiger J., Bender A., Möller H.J., Klopstock T., Rujescu D. Creatine protects against excitoxicity in an in vitro model of neurodegeneration. PLoS One 2012, 7:e30554.
30. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 1996, 66:2004-2010.
31. Gomez-Lazaro M., Galindo M.F., Concannon C.G., Segura M.F., Fernandez-Gomez F.J., Llecha N., Comella J.X., Prehn J.H., Jordan J. 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J Neurochem 2008, 104:1599-1612.
32. Gong L., Zhang Q.L., Zhang N., Hua W.Y., Huang Y.X., Di P.W., Huang T., Xu X.S., Liu C.F., Hu L.F., Luo W.F. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway. J Neurochem 2012, 123:876-885.
33. Gould T.D., Manji H.K. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002, 53:687-697.
34. Gu M., Cooper J.M., Taanman J.W., Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998, 44:177-186.
35. Hanada M., Feng J., Hemmings B.A. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 2004, 1697:3-16.
36. Hattingen E., Magerkurth J., Pilatus U., Mozer A., Seifried C., Steinmetz H., Zanella F., Hilker R. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009, 132:3285-3297.
37. Hemmer W., Wallimann T. Functional aspects of creatine kinase in brain. Dev Neurosci 1993, 15:249-260.
38. Hosamani R., Ramesh S.R., Muralidhara Attenuation of rotenone-induced mitochondrial oxidative damage and neurotoxicty in Drosophila melanogaster supplemented with creatine. Neurochem Res 2010, 35:1402-1412.
39. Huang T.J., Verkhratsky A., Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol Cell Neurosci 2005, 28:42-54.
40. 2+/calmodulin-dependent protein kinase II. Biochem J 2002, 364:593-611.
41. Huse D.M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005, 20:1449-1454.
42. Hwang Y.P., Jeong H.G. The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett 2008, 582:2655-2662.
43. Hwang Y.P., Jeong H.G. Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol 2010, 242:18-28.
44. Ikeda Y., Tsuji S., Satoh A., Ishikura M., Shirasawa T., Shimizu T. Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 2008, 107:1730-1740.
45. Jiang B.H., Zheng J.Z., Vogt P.K. An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. Proc Natl Acad Sci U S A 1998, 95:14179-14183.
46. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7:1421-1434.
47. Juravleva E., Barbakadze T., Mikeladze D., Kekelidze T. Creatine enhances survival of glutamate-treated neuronal/glial cells, modulates Ras/NF-kappaB signaling, and increases the generation of reactive oxygen species. J Neurosci Res 2005, 79:224-230.
48. Kao T.C., Shyu M.H., Yen G.C. Neuroprotective effects of glycyrrhizic acid and 18beta-glycyrrhetinic acid in PC12 cells via modulation of the PI3K/Akt pathway. J Agric Food Chem 2009, 57:754-761.
49. Kelly A., Lynch M.A. Long-term potentiation in dentate gyrus of the rat is inhibited by the phosphoinositide 3-kinase inhibitor, wortmannin. Neuropharmacology 2000, 39:643-651.
50. Koh J.Y., Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 1987, 20:83-90.
51. Kostrzewa R.M., Jacobowitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev 1974, 26:199-288.
52. Kumar R., Agarwal A.K., Seth P.K. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995, 64:1703-1707.
53. Lehmensiek V., Tan E.M., Liebau S., Lenk T., Zettlmeisl H., Schwarz J., Storch A. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. Neurochem Int 2006, 48:329-340.
54. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009, 18:R48-R59.
55. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
56. Li Y., Luo F., Wei L., Liu Z., Xu P. Knockdown of glycogen synthase kinase 3 beta attenuates 6-hydroxydopamine-induced apoptosis in SH-SY5Y cells. Neurosci Lett 2011, 487:41-46.
57. Levites Y., Amit T., Youdim M.B., Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 2002, 277:30574-30580.
58. Lin E., Cavanaugh J.E., Leak R.K., Perez R.G., Zigmond M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 2008, 86:108-117.
59. Luo F., Wei L., Sun C., Chen X., Wang T., Li Y., Liu Z., Chen Z., Xu P. HtrA2/Omi is involved in 6-OHDA-induced endoplasmic reticulum stress in SH-SY5Y cells. J Mol Neurosci 2012, 47:120-127.
60. Maher P. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci 2001, 21:2929-2938.
61. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., Kaddurah-Daouk R., Beal M.F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999, 157:142-149.
62. Mattson M.P., Pedersen W.A., Duan W., Culmsee C., Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci 1999, 893:154-175.
63. Mnich K., Finn D.P., Dowd E., Gorman A.M. Inhibition by anandamide of 6-hydroxydopamine-induced cell death in PC12 cells. Int J Cell Biol 2010, 2010:818497.
64. Moriguchi S., Yabuki Y., Fukunaga K. Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. J Neurochem 2012, 120:541-551.
65. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. J Immunol Methods 1983, 65:55-63.
66. Mu X., He G., Cheng Y., Li X., Xu B., Du G. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav 2009, 92:642-648.
67. Nagao M., Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci Lett 2009, 449:103-107.
68. NINDS NET-PD Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006, 66:664-671.
69. Noyes K., Liu H., Temkin-Greener H. Cost of caring for Medicare beneficiaries with Parkinson's disease: impact of the CMS-HCC risk-adjustment model. Dis Manag 2006, 9:339-348.
70. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 1999, 821:433-442.
71. Ossola B., Lantto T.A., Puttonen K.A., Tuominen R.K., Raasmaja A., Männistö P.T. Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death. J Neurosci Res 2012, 90:682-690.
72. Parada E., Egea J., Romero A., del Barrio L., García A.G., López M.G. Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via α7 nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway. Free Radic Biol Med 2010, 49:1815-1821.
73. Perumal A.S., Tordzro W.K., Katz M., Jackson-Lewis V., Cooper T.B., Fahn S., Cadet J.L. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res 1989, 504:139-141.
74. Plyte S.E., Hughes K., Nikolakaki E., Pulverer B.J., Woodgett J.R. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1992, 1114:147-162.
75. Poewe W., Gauthier S., Aarsland D., Leverenz J.B., Barone P., Weintraub D., Tolosa E., Dubois B. Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract 2008, 62:1581-1587.
76. Quesada A., Ogi J., Schultz J., Handforth A. C-terminal mechano-growth factor induces heme oxygenase-1-mediated neuroprotection of SH-SY5Y cells via the protein kinase Cε{lunate}/Nrf2 pathway. J Neurosci Res 2011, 89:394-405.
77. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., Yancopoulos G.D., Glass D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001, 3:1009-1013.
78. Schapira A.H. Progress in Parkinson's disease. Eur J Neurol 2008, 15:1.
79. Schlattner U., Tokarska-Schlattner M., Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006, 1762:164-180.
80. Sobrado M., Roda J.M., Lopez M.G., Egea J., Garcia A.G. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 2004, 365:32-136.
81. Song B., Lai B., Zheng Z., Zhang Y., Luo J., Wang C., Chen Y., Woodgett J.R., Li M. Inhibitory phosphorylation of GSK-3 by CaMKII couples depolarization to neuronal survival. J Biol Chem 2010, 285:41122-41134.
82. Tian L.L., Zhou Z., Zhang Q., Sun Y.N., Li C.R., Cheng C.H., Zhong Z.Y., Wang S.Q. Protective effect of (+/-) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells. Cell Physiol Biochem 2007, 20:1019-1032.
83. Tiong C.X., Lu M., Bian J.S. Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. Br J Pharmacol 2010, 161:467-480.
84. Tirmenstein M.A., Hu C.X., Scicchitano M.S., Narayanan P.K., McFarland D.C., Thomas H.C., Schwartz L.W. Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicol In Vitro 2005, 19:471-479.
85. Wallimann T., Schnyder T., Schlegel J., Wyss M., Wegmann G., Rossi A.M., Hemmer W., Eppenberger H.M., Quest A.F. Subcellular compartmentation of creatine kinase isoenzymes, regulation of CK and octameric structure of mitochondrial CK: important aspects of the phosphoryl-creatine circuit. Prog Clin Biol Res 1989, 315:159-176.
86. Wallimann T., Wyss M., Brdiczka D., Nicolay K., Eppenberger H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992, 281:21-40.
87. 2+/calmodulin-dependent kinases in posttetanic potentiation at input selective glutamatergic pathways. Proc Natl Acad Sci U S A 1998, 95:7133-7138.
88. Woznicki D.T., Walker J.B. Formation of a supplemental long time-constant reservoir of high energy phosphate by brain in vivo and in vitro and its reversible depletion by potassium depolarization. J Neurochem 1979, 33:75-80.
89. Yang P.C., Yang C.H., Huang C.C., Hsu K.S. Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity. J Biol Chem 2008, 283:2631-2643.
90. Yong-Kee C.J., Salomonczyk D., Nash J.E. Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease. Neurotox Res 2011, 19:519-526.
91. Zhang Z., Cui W., Li G., Yuan S., Xu D., Hoi M.P., Lin Z., Dou J., Han Y., Lee S.M. Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCα and PI3K/AKT signaling pathways. J Agric Food Chem 2012, 60:8171-8182.